2. Academic Validation
  3. Discovery of Potent and Selective Inhibitors of Wild-Type and Gatekeeper Mutant Fibroblast Growth Factor Receptor (FGFR) 2/3

Discovery of Potent and Selective Inhibitors of Wild-Type and Gatekeeper Mutant Fibroblast Growth Factor Receptor (FGFR) 2/3

  • J Med Chem. 2022 Nov 24;65(22):15433-15442. doi: 10.1021/acs.jmedchem.2c01366.
Artem Shvartsbart 1,  Jeremy J Roach 2,  Michael R Witten 3,  Holly Koblish 4,  Jennifer J Harris 3,  Maryanne Covington 3,  Rodrigo Hess 3,  Luping Lin 5,  Michelle Frascella 3,  Lisa Truong 3,  Lynn Leffet 3,  Patricia Conlen 3,  Elham Beshad 2,  Ron Klabe 3,  Kamna Katiyar 3,  Laura Kaldon 3,  Ruth Young-Sciame 3,  Xin He 3,  Susan Petusky 3,  Kwang-Jong Chen 3,  April Horsey 3,  Hsiang-Ting Lei 3,  Leslie B Epling 3,  Marc C Deller 3,  Oleg Vechorkin 3,  Wenqing Yao 6
Affiliations

Affiliations

  • 1 Prelude Therapeutics, Wilmington, Delaware 19803, United States.
  • 2 Proteovant Therapeutics, King of Prussia, Pennsylvania 19406, United States.
  • 3 Incyte Corporation, Wilmington, Delaware 19803, United States.
  • 4 Ikena Oncology, Boston, Massachusetts 02210, United States.
  • 5 WuXi AppTec, Philadelphia, Pennsylvania 19112, United States.
  • 6 Synnovation Therapeutics, Wilmington, Delaware 19803, United States.
PMID: 36356320 DOI: 10.1021/acs.jmedchem.2c01366
Abstract

Upregulation of the Fibroblast Growth Factor receptor (FGFR) signaling pathway has been implicated in multiple Cancer types, including cholangiocarcinoma and bladder Cancer. Consequently, small molecule inhibition of FGFR has emerged as a promising therapy for patients suffering from these diseases. First-generation pan-FGFR inhibitors, while highly effective, suffer from several drawbacks. These include treatment-related hyperphosphatemia and significant loss of potency for the mutant kinases. Herein, we present the discovery and optimization of novel FGFR2/3 inhibitors that largely maintain potency for the common gatekeeper mutants and have excellent selectivity over FGFR1. A combination of meticulous structure-activity relationship (SAR) analysis, structure-based drug design, and medicinal chemistry rationale ultimately led to compound 29, a potent and selective FGFR2/3 inhibitor with excellent in vitro absorption, distribution, metabolism, excretion (ADME), and pharmacokinetics in rat. A pharmacodynamic study of a closely related compound established that maximum inhibition of downstream ERK phosphorylation could be achieved with no significant effect on serum phosphate levels relative to vehicle.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-151903S
    FGFR2/3 Inhibitor